JAK inhibitor selectivity: new opportunities, better drugs?

2024-9-9

Interferon disrupts immune and tissue homeostasis in SLE via CXCL13

2024-9-9

Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis

2024-9-9

An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis

2024-9-6

Molecular mimicry links SARS-CoV-2 infection and MIS-C

2024-9-5

Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy

2024-9-4

Guiding ILD management in systemic autoimmune rheumatic diseases

2024-9-4

Helicobacter pylori-induced citrullination linked to RA exacerbation

2024-9-4

Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases

2024-9-2

The immune health metric as an indicator of health and disease

2024-9-2

Is X chromosome inactivation a cause or effect of SLE?

2024-9-2

Macrophage-coated nanocarriers for gouty arthritis

2024-8-23

Advancing equity in genomic medicine for rheumatology

2024-8-22

PDZK1 downregulation linked to mitochondrial dysfunction in OA

2024-8-20

Ion channels in osteoarthritis: emerging roles and potential targets

2024-8-9

Behavioural therapy app for fibromyalgia

2024-8-8

The past 25 years in paediatric rheumatology: insights from monogenic diseases

2024-8-7

The role of obesity and adipose tissue dysfunction in osteoarthritis pain

2024-8-7

Advancements and challenges in CAR T cell therapy in autoimmune diseases

2024-8-6

Shedding light onto the immunometabolic effects of glucocorticoids

2024-8-1

Off-the-shelf CAR T cells for refractory autoimmunity

2024-7-29

UNC93B1 variants promote SLE via TLR activation

2024-7-26

Integrin signalling in joint development, homeostasis and osteoarthritis

2024-7-16

The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies

2024-7-11

Itaconate targets fibroblast-like synoviocytes in RA

2024-7-10

Update on the pathophysiology and treatment of primary Sjögren syndrome

2024-7-9

Pathogenic antibodies target stromal antigens in RA

2024-7-8

Integrin-mediated ILC2 adhesion protects against lupus nephritis

2024-7-8

How muscle influences bone health

2024-7-5

Mitophagy as a link between ECM stiffness and chondrocyte senescence

2024-6-21

Platelets in Kawasaki disease: mediators of vascular inflammation

2024-6-17

Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy

2024-6-10

The peculiar features, diversity and impact of citrulline-reactive autoantibodies

2024-6-10

BiTEing refractory RA

2024-6-10

COVID-19 linked to rise in anti-MDA5 autoimmunity

2024-6-5

PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade

2024-6-5

Wearable device for RA management?

2024-6-5

Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases

2024-6-3

Clarity for the language of race, ethnicity and genetic ancestry in rheumatology

2024-5-31

Publisher Correction: IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting

2024-5-23

Two sides of management recommendations for psoriatic arthritis

2024-5-21

Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development

2024-5-17

Can transcriptomics guide the management of SLE-associated APS?

2024-5-16

Recent advancements in cartilage tissue engineering innovation and translation

2024-5-13

Bone-modifying drugs slow OA progression

2024-5-7

Rethinking antiphospholipid syndrome to guide future management and research

2024-5-3

Adropin inhibits fibrosis in SSc

2024-5-3

Relapsing polychondritis: clinical updates and new differential diagnoses

2024-5-2

Granzyme serine proteases in inflammation and rheumatic diseases

2024-4-30

Treat-to-target or treat-to-dissolve strategy to improve gout treatment

2024-4-26